Oncotelic Therapeutics Featured in NetworkNewsAudio Editorial Highlighting How Late-Stage Drug Pipelines Drive Valuation in Biotech

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in a NetworkNewsAudio editorial titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech”, which examines how late-stage drug development assets are increasingly becoming key drivers of valuation in the biopharmaceutical sector. The editorial, supported by analysis from McKinsey & Company, highlights that companies often realize the majority of value creation as their products approach commercialization, reflecting reduced risk and clearer revenue visibility. This trend is directly relevant to Oncotelic’s oncology-focused pipeline and its strategic development approach.

The editorial underscores that as drug candidates advance through clinical trials, the associated risk decreases, leading to higher valuations. This phenomenon is particularly pronounced in the biotech industry, where the success of a single late-stage product can transform a company’s financial outlook. For Oncotelic, which is a clinical-stage biopharmaceutical company dedicated to developing oncology and immunotherapy products, this dynamic is critical. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.

The editorial’s focus on pipeline-driven valuation is particularly timely as biotech companies increasingly rely on their development pipelines to attract investment and justify market valuations. For investors, understanding how late-stage assets contribute to value creation is essential for making informed decisions. Oncotelic’s inclusion in this editorial highlights its potential to benefit from these industry trends as it advances its own candidates toward commercialization. The full editorial is available via NetworkNewsAudio, providing further insights into the relationship between drug development progress and company valuation in the biotech sector.